Inhibrx Biosciences, Inc. (INBX)

Market Cap	1.29B +533.7%
Revenue (ttm)	1.30M +550.0%
Net Income	-140.06M
EPS	-9.04
Shares Out	14.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	416,564
Open	83.11
Previous Close	83.11
Day's Range	82.88 - 89.89
52-Week Range	10.84 - 94.57
Beta	n/a
Analysts	Buy
Price Target	150.00 (+70.01%)
Earnings Date	May 13, 2026

About INBX

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: INBX
• Website: https://inhibrx.com

Analyst Summary

According to 3 analysts, the average rating for INBX stock is "Buy." The 12-month stock price target is $150.0, which is an increase of 70.01% from the latest price.

Price Target

$150.0

(70.01% upside)

Analyst Consensus: Buy